SI2497500T1 - Genska terapija za spinalno mišično atrofijo - Google Patents
Genska terapija za spinalno mišično atrofijoInfo
- Publication number
- SI2497500T1 SI2497500T1 SI200731873A SI200731873A SI2497500T1 SI 2497500 T1 SI2497500 T1 SI 2497500T1 SI 200731873 A SI200731873 A SI 200731873A SI 200731873 A SI200731873 A SI 200731873A SI 2497500 T1 SI2497500 T1 SI 2497500T1
- Authority
- SI
- Slovenia
- Prior art keywords
- gene therapy
- muscular atrophy
- spinal muscular
- spinal
- atrophy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6027—Vectors comprising as targeting moiety peptide derived from defined protein from viruses ssDNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82797706P | 2006-10-03 | 2006-10-03 | |
EP12157957.7A EP2497500B1 (en) | 2006-10-03 | 2007-10-03 | Gene therapy for spinal muscular atrophy |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2497500T1 true SI2497500T1 (sl) | 2017-01-31 |
Family
ID=39269037
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200731083T SI2066791T1 (sl) | 2006-10-03 | 2007-10-03 | Genska terapija za amiotrofično lateralno sklerozo in druge motnje hrbtenjače |
SI200731873A SI2497500T1 (sl) | 2006-10-03 | 2007-10-03 | Genska terapija za spinalno mišično atrofijo |
SI200732128T SI3146982T1 (sl) | 2006-10-03 | 2007-10-03 | Genska terapija za amiotrofično lateralno sklerozo in druge motnje hrbtenjače |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200731083T SI2066791T1 (sl) | 2006-10-03 | 2007-10-03 | Genska terapija za amiotrofično lateralno sklerozo in druge motnje hrbtenjače |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200732128T SI3146982T1 (sl) | 2006-10-03 | 2007-10-03 | Genska terapija za amiotrofično lateralno sklerozo in druge motnje hrbtenjače |
Country Status (13)
Country | Link |
---|---|
US (2) | US9890394B2 (sl) |
EP (4) | EP2497500B1 (sl) |
CN (3) | CN101528922A (sl) |
AR (1) | AR063113A1 (sl) |
CY (1) | CY1118477T1 (sl) |
DK (2) | DK2066791T3 (sl) |
ES (3) | ES2607060T3 (sl) |
HU (2) | HUE046709T2 (sl) |
LT (2) | LT3146982T (sl) |
PL (2) | PL2066791T3 (sl) |
PT (3) | PT2497500T (sl) |
SI (3) | SI2066791T1 (sl) |
WO (1) | WO2008042420A2 (sl) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2066791T1 (sl) | 2006-10-03 | 2013-01-31 | Genzyme Corporation | Genska terapija za amiotrofično lateralno sklerozo in druge motnje hrbtenjače |
JP5186693B2 (ja) * | 2008-01-16 | 2013-04-17 | 独立行政法人科学技術振興機構 | 低酸素状態にある細胞で増殖するウイルスまたは遺伝子を発現するウイルスベクター |
SI2424991T1 (sl) | 2009-05-02 | 2018-11-30 | Genzyme Corporation | Genska terapija za nevrodegenerativne motnje |
WO2013025963A2 (en) | 2011-08-17 | 2013-02-21 | President And Fellows Of Harvard College | Conversion of somatic cells into functional spinal motor neurons, and methods and uses thereof |
MX2017006216A (es) | 2014-11-14 | 2018-08-29 | Voyager Therapeutics Inc | Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela). |
SG11201703419UA (en) | 2014-11-14 | 2017-05-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
CA2975447C (en) * | 2015-01-30 | 2021-02-23 | The Regents Of The University Of California | Spinal subpial gene delivery system |
CL2015003024A1 (es) | 2015-10-09 | 2016-05-13 | Univ Chile | Método de tratamiento genético utilizando el virus aav-xbp1s/gfp, y su uso en la prevención y tratamiento de la esclerosis lateral amiotrofica. |
CA3018960C (en) | 2016-03-28 | 2023-09-26 | The Regents Of The University Of California | Method and composition for treating neuronal hyper-excitability |
KR102392236B1 (ko) | 2016-05-18 | 2022-05-03 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
MA46863A (fr) * | 2016-11-17 | 2019-09-25 | Kevin Foust | Administration intrathécale de virus adéno-associé recombinant codant pour la protéine 2 de liaison méthyl-cpg |
JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
CA3061652A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
JP2020531047A (ja) * | 2017-08-16 | 2020-11-05 | エッレジヴ1・ソチエタ・ア・レスポンサビリタ・リミタータ | 神経疾患及び神経損傷における使用のためのbpifb4タンパク質のvtftアイソフォーム |
US11707535B2 (en) | 2017-09-08 | 2023-07-25 | The Regents Of The University Of California | Method and composition for treating neuropathic pain |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
JP7502991B2 (ja) | 2017-10-16 | 2024-06-19 | ボイジャー セラピューティクス インコーポレイテッド | 筋萎縮性側索硬化症(als)の治療 |
US10980566B2 (en) | 2019-01-10 | 2021-04-20 | The Regents Of The University Of California | Subpial delivery system and methods of use |
USD963164S1 (en) | 2020-01-09 | 2022-09-06 | The Regents Of The University Of California | Surgical needle |
WO2023288086A2 (en) * | 2021-07-16 | 2023-01-19 | President And Fellows Of Harvard College | Enhancers driving expression in motor neurons |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8303626D0 (sv) | 1983-06-23 | 1983-06-23 | Kabigen Ab | A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced |
US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル. グラハム,フランク | 遺伝子治療のためのアデノウイルスベクター |
ATE314482T1 (de) | 1993-10-25 | 2006-01-15 | Canji Inc | Rekombinante adenoviren-vektor und verfahren zur verwendung |
PT733103E (pt) | 1993-11-09 | 2004-07-30 | Targeted Genetics Corp | Criacao de elevados titulos de vectores de aav recombinantes |
US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
JPH10501686A (ja) | 1994-04-13 | 1998-02-17 | ザ ロックフェラー ユニヴァーシティ | 神経系の細胞へのdnaのaav仲介送達 |
US5882914A (en) | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
WO1997039789A1 (en) | 1996-04-22 | 1997-10-30 | Medtronic, Inc. | Two-stage angled venous cannula |
US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
US20030104973A1 (en) * | 1997-08-21 | 2003-06-05 | Quark Biotech, Inc. | Hypoxia-regulated genes |
CA2311643C (en) * | 1997-12-04 | 2009-04-07 | Genzyme Corporation | Compositions and methods for inducing gene expression |
US6124131A (en) | 1998-08-25 | 2000-09-26 | The Johns Hopkins University School Of Medicine | Mutant hypoxia inducible factor-1 HIF-1 |
US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
ES2252293T3 (es) | 2000-09-18 | 2006-05-16 | Genzyme Corporation | Vectores de expresion que contienene promotores hibridos de ubiquitina. |
US6838430B2 (en) * | 2001-09-28 | 2005-01-04 | The Regents Of The University Of California | Use of HIF-1a variants to accelerate wound healing |
CA2471812C (en) * | 2001-12-21 | 2012-09-04 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery to motor neurons |
US7193053B2 (en) * | 2003-04-25 | 2007-03-20 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hypoxia-inducible factor 1alpha variants and methods of use |
GB2414934A (en) * | 2004-06-11 | 2005-12-14 | Gill Steven Streatfield | Treatment of Parkinson's disease with GDNF |
SI2066791T1 (sl) | 2006-10-03 | 2013-01-31 | Genzyme Corporation | Genska terapija za amiotrofično lateralno sklerozo in druge motnje hrbtenjače |
PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
-
2007
- 2007-10-03 SI SI200731083T patent/SI2066791T1/sl unknown
- 2007-10-03 EP EP12157957.7A patent/EP2497500B1/en active Active
- 2007-10-03 SI SI200731873A patent/SI2497500T1/sl unknown
- 2007-10-03 LT LT16184966T patent/LT3146982T/lt unknown
- 2007-10-03 ES ES12157957.7T patent/ES2607060T3/es active Active
- 2007-10-03 EP EP16184966.6A patent/EP3146982B1/en active Active
- 2007-10-03 PL PL07839216T patent/PL2066791T3/pl unknown
- 2007-10-03 PL PL12157957T patent/PL2497500T3/pl unknown
- 2007-10-03 CN CNA200780038545XA patent/CN101528922A/zh active Pending
- 2007-10-03 LT LTEP12157957.7T patent/LT2497500T/lt unknown
- 2007-10-03 SI SI200732128T patent/SI3146982T1/sl unknown
- 2007-10-03 EP EP07839216A patent/EP2066791B1/en active Active
- 2007-10-03 PT PT121579577T patent/PT2497500T/pt unknown
- 2007-10-03 ES ES07839216T patent/ES2391789T3/es active Active
- 2007-10-03 WO PCT/US2007/021272 patent/WO2008042420A2/en active Application Filing
- 2007-10-03 AR ARP070104379A patent/AR063113A1/es active IP Right Grant
- 2007-10-03 CN CN201610214446.3A patent/CN105770910A/zh active Pending
- 2007-10-03 DK DK07839216.4T patent/DK2066791T3/da active
- 2007-10-03 DK DK12157957.7T patent/DK2497500T3/da active
- 2007-10-03 EP EP19192274.9A patent/EP3632472A1/en active Pending
- 2007-10-03 HU HUE16184966A patent/HUE046709T2/hu unknown
- 2007-10-03 CN CN201810575782.XA patent/CN108853517A/zh active Pending
- 2007-10-03 PT PT161849666T patent/PT3146982T/pt unknown
- 2007-10-03 HU HUE12157957A patent/HUE031182T2/en unknown
- 2007-10-03 PT PT78392164T patent/PT2066791E/pt unknown
- 2007-10-03 ES ES16184966T patent/ES2757723T3/es active Active
-
2009
- 2009-04-03 US US12/417,910 patent/US9890394B2/en active Active
-
2016
- 2016-12-20 CY CY20161101325T patent/CY1118477T1/el unknown
-
2017
- 2017-12-29 US US15/858,303 patent/US10920245B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2497500T3 (pl) | Terapia genowa rdzeniowego zaniku mięśni | |
GB0620400D0 (en) | Spinal implant | |
EP2094350A4 (en) | GROUPED ELECTRODES FOR BACKMARK STIMULATION | |
IL194153A0 (en) | Compounds for the treatment of spinal muscular atrophy and other uses | |
IL197316A0 (en) | Buprenophine-wafer for drug substitution therapy | |
EP2117471A4 (en) | SPINAL IMPLANT | |
EP2094175A4 (en) | SPINE CROSS CONNECTORS | |
EP2078536A4 (en) | MEDICAL DEVICE | |
GB0602178D0 (en) | Therapeutic treatment | |
IL196559A0 (en) | Combination therapy | |
IL196702A0 (en) | Trauma therapy | |
GB0618930D0 (en) | Medical implant | |
IL196556A0 (en) | Combination therapy | |
GB0608655D0 (en) | Therapeutic Treatment | |
EP2180855A4 (en) | SPINAL CORRECTION DEVICE | |
EP2054061A4 (en) | COMBINATION THERAPY | |
GB0602768D0 (en) | Treatment of muscular dystrophy | |
HK1127776A1 (en) | 2,4-diaminoquinazolines for spinal muscular atrophy 24- | |
EP1957026A4 (en) | SPINE THERAPY DEVICE | |
GB0610909D0 (en) | Therapeutic treatment | |
ZA200902203B (en) | Combination therapy | |
EP2022454A4 (en) | WHEELCHAIR | |
EP2056850A4 (en) | THERAPEUTIC METHODS FOR TREATING NEUROPATHIC PAIN | |
GB0607153D0 (en) | Therapeutic Method | |
GB0617299D0 (en) | Compounds for imaging and therapy |